A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. - Wikidata - wikimedia - TriplyDB

A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

http://www.wikidata.org/entity/Q34116805

about

Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo Autotaxin-LPA receptor axis in the pathogenesis of lung diseases Regulation of T cell motility in vitro and in vivo by LPA and LPA2 Lysophospholipid receptors in drug discovery.The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.LPA receptor signaling: pharmacology, physiology, and pathophysiology.Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.Lysophospholipid receptor nomenclature review: IUPHAR Review 8.Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.Pathobiology of liver fibrosis: a translational success story Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface.Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay.Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Autotaxin and Endotoxin-Induced Acute Lung Injury Insights into the pharmacological relevance of lysophospholipid receptors.Lys39-Lysophosphatidate Carbonyl Oxygen Interaction Locks LPA1 N-terminal Cap to the Orthosteric Site and partners Arg124 During Receptor Activation Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia-induced lung injury in neonatal rats.Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation.Destabilization of Lysophosphatidic Acid Receptor 1 Reduces Cytokine Release and Protects Against Lung Injury.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis.Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts.Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice.AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin Adult Lysophosphatidic Acid Receptor 1-Deficient Rats with Hyperoxia-Induced Neonatal Chronic Lung Disease Are Protected against Lipopolysaccharide-Induced Acute Lung Injury.Lysophosphatidic acid-1-receptor targeting agents for fibrosis.Anti-fibrosis therapy and diabetic nephropathy.Targeted therapies for systemic sclerosis.Design of anticancer lysophosphatidic acid agonists and antagonists.Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Calcium Homeostasis and Ionic Mechanisms in Pulmonary Fibroblasts.Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma.New therapies for hepatic fibrosis.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

P2860

Q26741062-2E4C41DD-7FB1-4A2F-8C84-F9D354BBB770 Q26862679-B0274DEA-2587-4BAB-A885-DC80E63943E8 Q27320538-169E99D3-0538-4263-99D3-38018E9FAE55 Q27692680-9B3A6CDD-D102-42FD-8B6E-E7241E5009D5 Q28070412-490B5355-47E4-4D30-A9B6-2CC46D583B66 Q28534911-C8B82958-58AF-4977-83C6-73B3669F7F01 Q28585279-5E6CD96F-BC37-4D1B-98DE-3E762AD9B1D5 Q30486707-C240EA66-7500-4E45-8DB8-75D84C6579ED Q33756825-5E738224-0928-4C5C-A809-D3BB33FF7E3A Q33825153-88BC48A5-3551-4583-B927-7CA9E0D68BD7 Q33840143-AB5B6ABD-C457-4E93-B4AA-110CA5744962 Q34025135-40A775A9-17AD-47D1-A3B3-5BB03B1793A4 Q34292377-87B6BAD0-F787-4F6A-ABD0-D177FFA56CFA Q34462733-2F0B2F27-C6F0-4C22-BFD7-8A0628F9314E Q34476196-A7C91B60-BA30-404A-B27C-ED47C64BCD51 Q34995628-2B2C970E-124C-433B-B45E-FC53AD9C9667 Q35216929-A1D868BD-BEBC-4FFF-BD3A-EBC190673A1D Q35551835-C8B85195-EEB1-47AE-826E-5917C6AD74F4 Q35702586-D7AC9986-69AE-4D8A-9B5A-019D7E83A57C Q35853199-485B1D48-E97B-46CA-9F23-F2AA96140495 Q35974518-A68E4D74-EE86-4F99-9686-FAD2074BA8F4 Q36535430-28F044CD-6295-47C4-BCE0-A318C9A44F9E Q36727390-A4BD7C65-3AE7-40C7-81E5-0A0D68284941 Q36863295-EFC9DF39-52DB-4F88-8EBA-6E9C51E9E320 Q37221686-51F580BA-9A8A-47A9-BD5E-394CAE4DC92F Q37381549-166BEDF3-739D-4889-ADA0-09C1237A63E7 Q37532276-E7436462-CAB8-4D11-871A-0B62E5461349 Q37562363-54CE7B8C-F1A0-4DCB-85FE-F1C58E1E9074 Q37596497-1E3178EC-7CDF-4EA7-BC91-16184F0850C7 Q37699896-3502C331-7545-401B-ABD6-DD8E91A3C0A3 Q37714510-12904511-962F-4866-8AAA-F8C5F177AD9E Q37857284-174B7A25-877C-47BC-B0CD-828F3C68BEDC Q38014361-81A48BF6-BD66-456F-B528-1D0A6C0BA4C9 Q38097276-E4ADD4B5-301D-4D97-BAB3-BF06FD747208 Q38223013-C4E3B574-70D0-4259-BFA5-140FACA32A78 Q38320338-A3F42F4F-2D38-4D89-9444-2167833B9ACE Q38382787-E97590A8-0F36-4083-A8FE-0532ED48953A Q38446855-CCA80821-D4F0-4BFF-A9C8-F888AA324BDC Q38553309-D37E36A1-4157-4BF0-876E-93E48BC601EA Q38580461-48491A87-4067-43C8-ACCB-B8B7D13B1B1E

P2860

A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

http://www.wikidata.org/entity/Q34116805

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@ast

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@en

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@nl

type

label

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@ast

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@en

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@nl

prefLabel

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@ast

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@en

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@nl

P1433

Q34116805-6D72DC3A-6A26-47F6-A630-022DDF20C7B1

P1476

Q34116805-E049AF6B-E0F9-4E43-95D4-1CB6EBFCABFE

P2093

Q34116805-0CBBE357-5491-4DD0-9FB4-889F4B82B668

Q34116805-0D9C4400-E6D7-4D60-B005-F8200EF8BA9F

Q34116805-19D39C37-B711-4319-BCA7-5B6826BD1C70

Q34116805-40BA7F84-C4B4-4A3B-82A2-B903903FE2BF

Q34116805-53B147B9-9E35-49CC-AF36-4D284319B3A6

Q34116805-656E0701-280D-4A14-BD7F-7BBB71472A7E

Q34116805-7EC9ABA7-3D13-41D1-9EE7-EE921EFFA96E

Q34116805-811B1081-E924-49A0-9E45-12A9E46A600E

Q34116805-9F10A288-1C26-4C65-B4C9-CBF785921EAF

Q34116805-9F767A69-56AC-468A-B6B8-342CB240523C

P2860

Q34116805-007CE9CE-A4BF-4721-AFF5-0761A85D32E5

Q34116805-043CE69E-1A72-4D08-AE5B-4DB261B2AB1D

Q34116805-07D3E0CD-DFFE-4352-8668-249AE8E80BDE

Q34116805-0B76C12E-BA46-4802-838D-210EB1EF06E2

Q34116805-0E8E2B78-C0EE-484C-AEF6-9699C9AAC27C

Q34116805-1F1C6791-50D4-4A4E-AEF4-19B61F75FE47

Q34116805-241DEAFF-CC3F-4C49-9407-8D42E6C44F45

Q34116805-25552BA7-9B4B-40A5-B245-88D9D131614D

Q34116805-2AB4389D-1BA7-49B6-95C3-E13E9E58B94E

Q34116805-2DB1FA37-24D8-408B-8DEE-C84FFC137B67

P304

Q34116805-DAEE57A1-0EAA-404B-AEA0-563089FCAAC9

P31

Q34116805-0BB78E76-E271-44DE-AF09-9A0362251721

P356

Q34116805-BF6921C5-0364-4C69-8B0E-37D44A0BFEC2

P407

Q34116805-387A02F0-2FE4-44F5-8AD9-0EFA0BCE8864

P433

Q34116805-390BC118-09D2-40CB-8550-A66DA068F2E2

P478

Q34116805-2AA768DA-A442-4716-929D-73E0843964ED

P577

Q34116805-BFAC568F-FBF1-4430-AE5A-88D5A75A731C

P5875

Q34116805-15B80AB1-B700-4004-8A96-AC13DA321252

P698

Q34116805-F109E03B-89C8-45BE-93AA-AD335BCF521E

P921

Q34116805-35A5E13F-A828-4230-91C4-D3B97EBA016F

P932

Q34116805-C91305A4-6F93-44FF-995D-2C1B0949DDBF

P356

J.1476-5381.2010.00828.X

P1433

British Journal of Pharmacology

P1476

A novel, orally active LPA(1) ...... in the mouse bleomycin model.

@en

P2093

A M Santini

http://www.w3.org/2001/XMLSchema#string

C Chapman

http://www.w3.org/2001/XMLSchema#string

C S Baccei

http://www.w3.org/2001/XMLSchema#string

D S Lorrain

http://www.w3.org/2001/XMLSchema#string

J F Evans

http://www.w3.org/2001/XMLSchema#string

J H Hutchinson

http://www.w3.org/2001/XMLSchema#string

J S Swaney

http://www.w3.org/2001/XMLSchema#string

K J Stebbins

http://www.w3.org/2001/XMLSchema#string

L D Correa

http://www.w3.org/2001/XMLSchema#string

P C Prodanovich

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular and molecular mechanisms of fibrosis

Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder

Myofibroblasts and mechano-regulation of connective tissue remodelling

Pulmonary fibrosis: pathogenesis, etiology and regulation

MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis

Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase.

Incidence and prevalence of idiopathic pulmonary fibrosis.

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

P304

1699-1713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.2010.00828.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45280648

http://www.w3.org/2001/XMLSchema#string

P698

20649573

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

2936842

http://www.w3.org/2001/XMLSchema#string